Because of COVID-19 pandemic the 6th Theranostics World Congress (TWC) 2021 was postponed and held at Jun 24-26, 2022 in Wiesbaden instead of Santiago de Chile. As the co-initiator and a member of congress committee, Prof. Dr. Frank Rösch and Prof. Dr. Richard P. Baum hosted hundreds of scientists, specialists, and students worldwide in the research field of theranostics, nuclear medicine and radiopharmaceuticals. This congress focused on the new developments in the area of radioisotope production, radiochemistry and radiopharmacy, especially on the application of radiomolecular precision medicine (RPM) for cancer diagnosis and treatment, such as neuroendocrine tumors, prostate cancers etc.
Fibroblast Activation Protein (FAP) inhibitors are extremely promising targeting vectors to address the microenvironment of various solid tumors. Prof. Dr. Rösch presented research radiotheranostics combining two FAP inhibitors. Our radiotherapeutic agent with dimeric structure shows extended retention time in tumors and better clinical outcome post therapy. Moreover, the agent works on various tumors, such as thyroid, breast, and ovarian and more. Is the FAP dimeric agent the next generation medicine for cancer therapy?
